Author(s):
Jitendra Yadav, Dolly Dewangan, Kamraj, Krity Gupta, Manish Kumar Sahu, Parimal Verma, Prashant Kumar Sahu, Shweta Sinha, Aakanksha Sinha, S. J. Daharwal
Email(s):
jy7288096@gmail.com
DOI:
10.52711/2321-581X.2025.00012 
Address:
Jitendra Yadav*, Dolly Dewangan, Kamraj, Krity Gupta, Manish Kumar Sahu, Parimal Verma, Prashant Kumar Sahu, Shweta Sinha, Aakanksha Sinha, S. J. Daharwal
University Institute of Pharmacy, Pt. Ravishankar Shukla University, Raipur (C.G).
*Corresponding Author
Published In:
Volume - 16,
Issue - 3,
Year - 2025
ABSTRACT:
Ranolazine, a piperazine derivative, is an anti-anginal drug used to treat cardiac ischemia. In myocardial ischemia, it works by altering sodium-dependent calcium channels, so avoiding calcium overload, which results in heart ischemia. When taken in conjunction with other treatments such as beta-blockers, nitrates, calcium channel blockers, antiplatelet medication, lipid-lowering medicines, ACE inhibitors, and angiotensin receptor blockers, ranolazine is helpful for treating chronic angina. A new anti-ischemic drug called ranolazine inhibits reverse mode sodium-calcium exchange, which lowers diastolic calcium accumulation by suppressing late INa to prevent cellular sodium overload. By directly addressing myocardial ischemia, this technique can raise coronary blood flow and diastolic tone. The several analytical techniques that have been documented for the determination of ranolazine in synthetic mixtures are represented in this review article. Chromatographic techniques were reported, including GC, LC-MS, RP-HPLC, HPTLC, HPLC, and LC-MS/MS.
Cite this article:
Jitendra Yadav, Dolly Dewangan, Kamraj, Krity Gupta, Manish Kumar Sahu, Parimal Verma, Prashant Kumar Sahu, Shweta Sinha, Aakanksha Sinha, S. J. Daharwal. Analytical Methodologies for Ranolazine estimation: A brief review. Research Journal of Engineering and Technology. 2025; 16(3):127-6. doi: 10.52711/2321-581X.2025.00012
Cite(Electronic):
Jitendra Yadav, Dolly Dewangan, Kamraj, Krity Gupta, Manish Kumar Sahu, Parimal Verma, Prashant Kumar Sahu, Shweta Sinha, Aakanksha Sinha, S. J. Daharwal. Analytical Methodologies for Ranolazine estimation: A brief review. Research Journal of Engineering and Technology. 2025; 16(3):127-6. doi: 10.52711/2321-581X.2025.00012 Available on: https://ijersonline.org/AbstractView.aspx?PID=2025-16-3-4
REFERENCE:
1. Rousseau MF, Pouleur H, Cocco G, Wolff AA. Comparative efficacy of ranolazine versus atenolol for chronic angina pectoris. The American Journal of Cardiology. 2005 Feb 1;95(3):311-6.
2. Djamgoz MB. Ranolazine: a potential anti-metastatic drug targeting voltage-gated sodium channels. British Journal of Cancer. 2024 May 18; 130(9):1415-9.
3. Nalawade V, Gide P, Nunnavare G, Phale M. Development and validation of a LLE-HPLC method for the determination of ranolazine in human plasma. Int. J. Ph. Sci. 2010 Jan;2(1).
4. Markus J. Clinical pharmacokinetics of ranolazine; Clin. P kinetics. 2006; 45(5):469-91.
5. Stanley WC. Ranolazine: new approach for the treatment of stable angina pectoris. Expert Review of Cardiovascular Therapy. 2005 Sep 1; 3(5):821-9.
6. Extended-release ranolazine [Ranexa; CV Therapeutics] has been launched in the US for the treatment of chronic angina, Inpharma, Adis International Publisher, pp18-18(1)-2006.
7. Ling H, Fu S, Xu M, Wang B, Li B, Li Y, Liu X, Zhang X, Wang Q, Li A, Liu M. Ranolazine for improving coronary microvascular function in patients with nonobstructive coronary artery disease: a systematic review and meta-analysis with a trial sequential analysis of randomized controlled trials. Quantitative Imaging in Medicine and Surgery. 2024 Jan 9;14(2):1451.
8. Patil P, Rangari S, Patil P. Research on analytical methods of analysis of Ranolazine: A Review. Himalayan Journal of Health Sciences (HJHS). 2020:30-40.
9. Patel Vishakha. D. Raj Hasumati, Gheewala Nirav, A Review on Analytical Methods for Ranolazine determination in synthetic mixture; Pharma Tutor; 2016; 4(4); 28-31
10. Keating GM. Ranolazine: a review of its use in chronic stable angina pectoris. Drugs. 2008 Dec; 68(17):2483-503
11. Hasenfuß G, Maier LS. Mechanism of action of the new anti-ischemia drug ranolazine. Clinical Research in Cardiology. 2008 Apr; 97(4): 222-6.
12. Chaitman BR, Pepine CJ, Parker JO, Skopal J, Chumakova G, Kuch J, Wang W, Skettino SL, Wolff AA, Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators, Combination Assessment of Ranolazine In Stable Angina (CARISA) Investigators. Effects of ranolazine with atenolol, amlodipine, or diltiazem on exercise tolerance and angina frequency in patients with severe chronic angina: a randomized controlled trial. JAMA. 2004 Jan 21; 291(3): 309-16.
13. Chaitman BR, Skettino SL, Parker JO, Hanley P, Meluzin J, Kuch J, Pepine CJ, Wang W, Nelson JJ, Hebert DA, Wolff AA. Anti-ischemic effects and long-term survival during ranolazine monotherapy in patients with chronic severe angina. Journal of the American College of Cardiology. 2004 Apr 21; 43(8): 1375-82.
14. Tani M, Neely JR. Role of intracellular Na+ in Ca2+ overload and depressed recovery of ventricular function of reperfused ischemic rat hearts. Possible involvement of H+-Na+ and Na+-Ca2+ exchange. Circulation research. 1989 Oct;65(4):1045-56.
15. Hale SL, Shryock JC, Belardinelli L, Sweeney M, Kloner RA. Late sodium current inhibition as a new cardioprotective approach. Journal of Molecular and Cellular Cardiology. 2008 Jun 1; 44(6): 954-67.
16. Létienne R, Vié B, Puech A, Vieu S, Le Grand B, John GW. Evidence that ranolazine behaves as a weak β1-and β2-adrenoceptor antagonist in the rat cardiovascular system. Naunyn-Schmiedeberg's Archives of Pharmacology. 2001 Apr;363(4):464-71
17. Bairey Merz CN, Handberg EM, Shufelt CL, Mehta PK, Minissian MB, Wei J, Thomson LE, Berman DS, Shaw LJ, Petersen JW, Brown GH. A randomized, placebo-controlled trial of late Na current inhibition (ranolazine) in coronary microvascular dysfunction (CMD): impact on angina and myocardial perfusion reserve. European Heart Journal. 2016 May 14; 37(19): 1504-13.
18. Jerling M. Clinical pharmacokinetics of ranolazine. Clin Pharmacokinet. 2006; 45: 469–491.
19. McCormack JG, Barr RL, Wolff AA, Lopaschuk GD. Ranolazine stimulates glucose oxidation in normoxic, ischemic, and reperfused ischemic rat hearts. Circulation. 1996 Jan 1; 93(1):135-42.
20. Fihn SD, Gardin JM, Abrams J, Berra K, Blankenship JC, Dallas AP, Douglas PS, Foody JM, Gerber TC, Hinderliter AL, King SB. 2012 ACCF/AHA/ACP/AATS/PCNA/SCAI/STS guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association task force on practice guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. Journal of the American College of Cardiology. 2012 Dec 18; 60(24):e44-164.
21. Lavanya G, Sunil MM, Eswarudu MM, Eswaraiah MC, Harisudha K, Spandana BN. Analytical method validation: an updated review. International Journal of Pharmaceutical Sciences and Research. 2013 Apr 1; 4(4):1280..
22. Pranshu T, Singh RP, Vikash J. Validation: A critical parameter for quality control of pharmaceuticals. Journal of Drug Delivery and Therapeutics. 2012; 2(3):34-40.
23. Ravisankar, P., S. Gowthami, and G. Devlala Rao. A review on analytical method development. Indian Journal of Research in Pharmacy and Biotechnology. 2014; 2(3): 1183
24. Vidushi Y, Meenakshi B, Bharkatiya M. A review on HPLC method development and validation. Res J Life Sci, Bioinform, Pharm Chem Sci. 2017; 2(6): 178.
25. Suresh Babu VV, Sudhakar V, Murthy TE. Validated HPLC method for determining related substances in compatibility studies and novel extended release formulation for ranolazine. J Chromatograph Separat Techniq. 2014; 5(209): 2.
26. Laha TK, Padhy DR, Sen S. A validated stability indicating reversed phase high performance liquid Chromatographic method of ranolazine dihydrochloride and Characterization of its degradation products. International Journal of Pharmacy and Pharmaceutical Sciences. 2013; 5(1): 61-6.
27. Madhavi A, Subba Rao DV, Srinivasu P, Naidu A. Development and validation of a new analytical method for the determination of related components and assay of ranolazine in bulk drug and pharmaceutical dosage forms by LC. Chromatographia. 2009 Jul; 70(1): 333-8
28. Bai S, Gao H, Qu H, Liang Y, Li Y, Zheng Z, Wang X, Hao G. Quantitative determination of Ranolazine in human plasma by high performance liquid chromatography-tandem mass spectrometry. Northwest Pharmaceutical Journal. 2011(4):249-51. Patel R.C, Rathod D.K, Patel P.R, Patel V.S, Estimation of Ranolazine Hydrochloride by Spectrophotometric and RP-HPLC in tablet dosage forms. International Journal of Pharmaceutical and Applied Sciences. 2010; 1(2): 79-83
29. G.L, K.H, Agarwal N, Development and validation of stability indicating RP-HPLC method for estimation of Ranolazine in bulk and tablet dosage form. International Research Journal of Pharmaceutical and Applied Sciences. 2012; 2(5): 217-223
30. Soujanya A, K.V.S, Puttagunta S, Method Development and Validation for estimation of Ranolazine in its bulk and tablet dosage form. International Journal of Inventions in Pharmaceutical Sciences. 2013; 1(4): 363-369
31. Ganji R, D. R, G. S, Jayapal G, P. R, Srilakshmi V, Development and Validation of stability indicating RP-LC method for estimation of Ranolazine in bulk and its Pharmaceutical formulation., American Journal of analytical Chemistry, 2012, 3, 378-384
32. Boovizhikannan T, Palanirajan V, Estimation of Ranolazine using Reverse phase High Performance liquid Chromatography Technique. American Journal of Pharma Tech Research. 2012; 2(6),
33. Laha T, Padhy D, Sen S, A Validated stability indicating reversed phase high performance liquid chromatography method of Ranolazine Dihydrochloride and characterization of its degradation products. International Journal of Pharmacy and Pharmaceutical Sciences. 2013; 5(1): 61-66
34. Malati V, Reddy A.R, Mukkanti K, Suryanarayana M.V, A novel reversed phase stability indicating RP-UPLC method for the quantitative determination of fifteen related substances in Ranolazine drug substance and drug product. J. Talanta. 2012; 97: 563-373.
35. Tan Q, Zhu R, Li H, Fang P, Yan M, Zhang Q, Peng W, Development and Validation of a,sensitive,U HPLC-MS/MS, method, with electrospray ionization for quantitation of Ranolazine in human plasma: Application to a clinical pharmacokinetic study. Journal of Chromatography B, 2012; 901: 119-124
36. Parvatha reddy S, Desam N, Nuthalapati M, B.T, Development and Validation of HPLC and UV methods for estimation of Ranolazine in Bulk and Marketed formulation. International Journal of Innovative Pharmaceutical Sciences and Research. 2014; 2(5): 1042-1058
37. Ermer J, Vogel M. Applications of hyphenated LC‐MS techniques in pharmaceutical analysis. Biomedical Chromatography. 2000 Oct; 14(6): 373-83
38. Bhardwaj SK, Dwivedi K, Agarwal DD. A review: GC method development and validation. Int J Anal Bioanal Chem. 2016; 6(1):1-7
39. Sharma T, Moitra S.K, Si.S.C, Sankar D.G, Stability indicating LC method for the determination of Ranolazine Hydrochloride in the bulk drug and in pharmaceutical dosage form. International Journal of Pharmacy and Pharmaceutical Sciences. 2011; 3(4): 327-332
40. Lei T, Juanjuan J, Yiling H, Lu H, Hong L, Yishi L. Sensitive quantification of Ranolazine in human plasma by liquid chromatography-tandem mass spectrometry with positive electrospray ionization. Journal of Chromatography B, 2007; 846(1-2): 346-350
41. Zhao L, Li H, Jiang Y, Piao R, Li P, Gu J. Determination of Ranolazine in human plasma by liquid chromatographic-tandem Mass Spectrometric assay. Journal of Chromatographic Science. 2008; 46(8): 697-700
42. Luo X, Zhai Z, Wu X, Shi Y, Chen L, Li Y. Analytical and semi-preparative resolution of Ranolazine enantiomers by, liquid, chromatography using polysaccharide chiral stationary phases. Journal of Separation Science. 2006; 29(1): 164-171
43. A.M, Venkata S.D, P.S, A.N, Development and Validation of a new analytical method for the Determination of related components and assay of Ranolazine in bulk drug and pharmaceutical dosage forms by LC., J. Chromatographia, 2009; 70(1): 333-338
44. Liang Y, Xie L, Liu XD, Chen WD, Lu T, Xiong Y, Wang Gj, Simple, sensitive and rapid liquid chromatography/atmospheric pressure chemical ionization mass spectrometric method for the quantitation of Ranolazine in rat plasma., Rapid Commun Mass Spectrum. 2006; 20(4): 523-52
45. Herron W.J, Eadie J, Penman A.D, Estimation of Ranolazine and eleven phase I metabolites in human plasma by liquid chromatography-atmospheric pressure chemical ionization mass spectrometry with selected-ion monitoring. Journal of Chromatography A. 1995; 712(1): 50-60
46. Zhong J, Liu X.Q, Chen Y, Zhao X.P, Wang Y.S, Wang G.J. Determination of Ranolazine in rat plasma by liquid chromatography-electrospray ionization mass spectrometry., J. Chromatographia. 2006; 63(3-4): 123-127
47. Tang JY, Wang w, Li L, Zhang CG, Wang DM, Sun L, Analysis of primary metabolites of Ranolazine in dog urine by LC-MS(n)., Yao Xue Xue Bao. 2012; 47(8): 1031-1038
48. Simões RA, Barth T, Bonato PS. Enantioselective analysis of ranolazine and desmethyl ranolazine in microsomal medium using dispersive liquid–liquid microextraction and LC–MS/MS. Bioanalysis. 2013 Jan 1;5(2):171-83.
49. Wang Y, Chen X, Sun Z, Yang Y, Liu W, Zhong D, Development and Validation of a sensitive LC MS/MS assay for simultaneous quantitataion of Ranolazine and its three metabolites in human plasma., Journal of Chromatography B analyt Technology Biomed Life Sciences. 2012; 10(6): 889 890
50. Bhaumik U, Ghosh A, Sarkar A, BoseA, Selvan P, Sengupta P, Chakraborty U, Ghosh D, Pal T, Determination of Ranolazine in human plasma by LC-MS/MS and its application in bioequivalence study., Journal of Pharmaceutical and Biomedical Analysis. 2008; 48(5): 1404-1410
51. Ya-Lin Ye, Xue-Mei Yang. Determination of Residual Solvents in Ranolazine By Headspace Gas Chromatography. Journal of Southern Medical University. 2008; 28(1): 134-135.
52. Patel RB, Patel MR, Batel BG. Experimental aspects and implementation of HPTLC. InHigh-performance thin-layer chromatography (HPTLC) 2011 (pp. 41-54). Springer, Berlin, Heidelberg.
53. A. Khedkar, et al. Stability Indicating Method Development and Validation of Ranolazine Hydrochloride in Bulk and Tablet dosage form by HPTLC. International Journal of Pharmaceutical and Clinical Research. 2015; 7(1): 77-83.
54. Chakraborty R, Pal K, Shaiba M, Sangepu N, Sridevi P. High performance thin-layer chromatographic estimation of ranolazine. Res. J. Pharm. Biol. Chem. Sci. 2010; 4: 152-7.
55. Abburu SR, Alapati ML, Dadhich AS, Rao MK. Determination of ranolazine in tablet formulations by high-performance thin-layer chromatography—mass spectrometry using reflectance scanning densitometry. JPC-Journal of Planar Chromatography-Modern TLC. 2016 Jun; 29(3): 190-4
56. Nnachi AB. Advances in UV spectroscopy for monitoring the environment. RIJBAS. 2024; 3(1): 82.
57. Maurya RK, Kumar GP, Singh G, Malik J, Singh SP, Tiwari A. Recent developments in UV-Spectroscopy techniques for quantitative analysis in pharmaceutical dosage forms.
58. Sharma A, Prakash D, Singh SK. Development and validation of UV spectrophotometric method for the estimation of ranolazine in bulk drug and pharmaceutical formulation. Int J Chem Tech Res. 2010 Oct; 2(4): 1945-8.
59. Singh RK, Patel PS, Malik P, Singh TP. Nanodrop Spectrophotometric method development and validation for estimation of Ranolazine in Their Bulk. International Journal of Pharmaceutical Sciences and Research. 2011 Apr 1;2(4):985.
60. Ugale JB, Mulgund SV. Development and Validation of UV Spectrophotometric Area under cure method for Quantitative Estimation of Ranolazine in API and Tablet Formulation. World Journal of Pharmaceutical Research. 2015 Mar 16;4(5):2665-72.
61. Nishith, C., Development and validation of analytical methods for quantitative estimation of ranolazine. 2014. (/jspui/handle/123456789/194).
62. Asifa Nahid, Haritha Pavani, Development and validation of HPLC method for simultaneous determination of Ranolazine and Dronedarone in bulk and pharmaceutical dosage forms. Indian Journal of Research in Pharmacy and Biotechnology. 2(6):1524-1528.
63. Sharma A, Prakash D, Singh SK. Development and validation of UV spectrophotometric method for the estimation of ranolazine in bulk drug and pharmaceutical formulation. Int J Chem Tech Res. 2010 Oct; 2(4):1945-8.
64. Kmail N, Shantier S, Gadkariem E. Derivative Spectrophotometric Methods for the Analysis and Stability Studies of Ranolazine in Bulk and Dosage Forms. Hacettepe University Journal of the Faculty of Pharmacy. 2022; 42(1):13-21.
65. Killedar S, Pawar A, Nadaf S, Nale A, Tamboli U, Pishawikar S. Novel analytical method development for some amide group containing drugs using Bougainvillea spectabilis bract extracts. Asian Pacific Journal of Tropical Medicine. 2014 Sep 1; 7: S560-7.
66. Vyas AJ, Raval DH, Patel AI, Patel AB, Patel NK, Chudasama A. First order derivative spectrophotometric estimation of ranolazine and metformin hydrochloride in synthetic mixture. Chem Methodol. 2020; 4: 605-13.
67. Patel J, Patel P, Mashru R. Novel UV-spectrophotometric and RP-HPLC method development and validation of simultaneous estimation of ranolazine and metformin HCl: A statistical analysis. Pharm Innov J. 2020; 9: 50-7.
68. Vyas K, Soniwala M, Vyas A, Shah N. Development of a UV visible spectrophotometric method for simultaneous estimation of ranolazine and metoprolol. Journal of Drug Delivery and Therapeutics. 2022 May 2; 12(3-S): 64-72.
69. Nahid A, Pavani H. Development and validation of HPLC method for simultaneous determination of Ranolazine and Dronedarone in bulk and pharmaceutical dosage forms. Indian Journal of Research in Pharmacy and Biotechnology. 2014 Nov 1; 2(6): 1524.